Last week has been a productive one for Chester County biopharmaceutical and medical technology companies, writes John George for the Philadelphia Business Journal.

Wayne-based Palvella Therapeutics, which specializes in treatments for uncommon genetic skin conditions, has broadened its partnership with Ligand Pharmaceuticals to expedite the development of Qtorin rapamycin, the company’s experimental treatment for microcystic lymphatic malformations.

Palvella will receive an upfront payment of $5 million as part of the deal.

Meanwhile, Aclaris Therapeutics, a Wayne biopharmaceutical company, has signed an exclusive patent license agreement with Sun Pharmaceutical Industries. The agreement covers the use of deuruxolitinib as an alopecia treatment.

Aclaris will receive an upfront payment of $15 million under the terms of the agreement. The company will also receive undisclosed regulatory and commercial milestone payments and royalties related to the deal.

Finally, Malvern medical technology company Neuronetics has been awarded expanded approval for its NeuroStar TMS therapy system by the Pharmaceuticals and Medical Devices Agency in Japan.

According to the company, Japanese regulators greenlit several proprietary innovations that “significantly advance the patient treatment experience” with NeuroStar for major depressive disorder treatment in Japan.

Read more about Palvella Therapeutics, Aclaris Therapeutics, and Neuronetics in the Philadelphia Business Journal.

______